Over the past few decades, considerable interest has been shown in developing nano-and microcarriers with biocompatible and biodegradable materials for medical and biotechnological applications. Microencapsulation is a technology capable of enhancing the survival rate of bacteria, providing stability in harsh environments. In the present paper, we developed a technology to encapsulate microorganisms within polyhydroxyalkanoate (PHA)-based microcapsules (MPs), employing a modified double emulsion solvent evaporation technique, with Pseudomonas putida KT2440 as a biotechnological model strain. The resulting MPs display a spherical morphology and an average particle size of 10 lm. The stability of the MPs was monitored under different conditions of storage and stress. The MPs remained stable for at least 24 days stored at 4°C in a water suspension. They exhibited greater tolerance to stress conditions; encapsulated cells remained viable for 2 h in alkaline solution and after 24 h of H 2 O 2 exposure at 10 and 20 mM. Results suggested the potential of MPs as a microcontainer of bacterial cells, even for biotechnological applications requiring high alkaline conditions and oxidative stress. We validated the potential applicability of the PHA-based microencapsulation method in other microorganisms by encapsulating the predatory bacterium Bdellovibrio bacteriovorus. Received

Background Within febrile neutropenic episodes, bacteremia is the most frequent cause. Capnocytophaga species bacteremia represents less than 3% of all etiologies, being an uncommon agent. Only a few pediatric cases have been reported in the literature. Case Presentation A 6-year-old male patient was diagnosed with acute lymphoblastic leukemia and a bone marrow relapse. He was admitted to our institution with an episode of febrile neutropenia with grade II mucositis. A nonhemolytic gram-negative rod was isolated from a blood culture, with gray colonies in blood agar at 48 hours of incubation. Capnocytophaga sputigena was identified by matrix-assisted laser desorption/ionization and time of flight. The patient was successfully treated with imipenem-cilastatin for 10 days. Conclusions Although this pathogen is uncommon, Capnocytophaga species bacteremia should be suspected as a causal agent in immunocompromised patients, particularly in cases of febrile neutropenia with oral cavity involvement.

No abstract